Patents by Inventor Eckhard Bender
Eckhard Bender has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10130633Abstract: The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: LA represents an optionally substituted methylene or ethylene group; LB represents —N(H)—C(?O)— or —C(?O)—N(H)—; R1 represents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or —N(R7)(Ci-C6-alkyl) group; R2 represents an optionally substituted 5- or 6-membered heteroaryl group; R3 represents an optionally substituted phenyl group.Type: GrantFiled: March 17, 2014Date of Patent: November 20, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Kai Thede, William Scott, Eckhard Bender, Stefan Golz, Andrea Hägebarth, Philip Lienau, Florian Puehler, Daniel Basting, Dirk Schneider, Manfred Möwes, Anja Richter, Ludwig Zorn, Ningshu Liu, Ursula Mönning, Franziska Siegel
-
Publication number: 20180148418Abstract: The present invention relates to amido-substituted cyclohexane compounds of general formula (I), in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredient.Type: ApplicationFiled: May 2, 2016Publication date: May 31, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Knut EIS, Jens ACKERSTAFF, Sarah WAGNER, Philipp BUCHGRABER, Detlev SÜLZLE, Simon HOLTON, Eckhard BENDER, Volkhart LI, Ningshu LIU, Franziska SIEGEL, Philip LIENAU, Michaela BAIRLEIN, Franz VON NUSSBAUM, Simon Anthony HERBERT, Marcus KOPPITZ
-
Publication number: 20180044306Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: February 16, 2016Publication date: February 15, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Kai THEDE, Eckhard BENDER, William J. SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PÜHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES, Jens GEISLER
-
Publication number: 20180042931Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) wherein LA represents *CH2** or *?**; wherein indicates the point of attachment to the carbonyl group, and ** indicates the point of attachment to R1; LB represents *N(H)—C(?O)** or *C(?O)—N(H)**; wherein * indicates the point of attachment to R2, and ** indicates the point of attachment to the phenyl group; R1 represents a group selected from: (AA); wherein * indicates the point of attachment to LA, R2 represents: (BB) wherein * indicates the point of attachment to R3, and ** indicates the point of attachment to LB R3 represents a group selected from: (CC); wherein * indicates the point of attachment to R2; R4 and R5 represent a hydrogen atom; and R6 represents a halogen atom or group selected from: —CH3, —O—CH3, —O—CHF2, —O—CF3, and —O-cyclopropyl; to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturingType: ApplicationFiled: February 16, 2016Publication date: February 15, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Kai THEDE, Eckhard BENDER, William J. SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PÜHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES
-
Patent number: 9884063Abstract: The present invention relates to amido-substituted azole compounds of general formula (I), in which X1, X2, R1, R2, R4, R5, R7 and R8 are as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.Type: GrantFiled: April 1, 2015Date of Patent: February 6, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Knut Eis, Jens Ackerstaff, Sarah Wagner, Daniel Basting, Stefan Golz, Eckhard Bender, Volkhart Min-Jian Li, Philip Lienau, Ningshu Liu, Franziska Siegel, Marcus Bauser, Detlev Sülzle, Simon Holton, Michaela Bairlein, Philipp Buchgraber, József Bálint
-
Publication number: 20180028507Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients, in which: R1 represents a group selected from: C1-C3-alkoxy-C2-C3-alkyl-, (A), (B), (C), (D), (E), (F), (G) or (H); wherein * indicates the point of attachment to the rest of the molecule; R2 represents a group selected from: (I), (J) or (K); wherein * indicates the point of attachment to the rest of the molecule.Type: ApplicationFiled: February 16, 2016Publication date: February 1, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Kai THEDE, Eckhard BENDER, William J. SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PÜHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES
-
Publication number: 20170114070Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: March 18, 2015Publication date: April 27, 2017Inventors: Kai THEDE, Eckhard BENDER, William SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PUEHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES, Jens GEISLER
-
Publication number: 20170107212Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: March 18, 2015Publication date: April 20, 2017Inventors: Kai THEDE, Eckhard BENDER, William SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PUEHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES, Jens GEISLER
-
Publication number: 20170020886Abstract: The present invention relates to amido-substituted azole compounds of general formula (I), in which X1, X2, R1, R2, R4, R5, R7 and R8 are as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: April 1, 2015Publication date: January 26, 2017Inventors: Knut EIS, Jens ACKERSTAFF, Sarah WAGNER, Daniel BASTING, Stefanü GOLZ, Eckhard BENDER, Volkhart Min-Jian LI, Philip LIENAU, Ningshu LIU, Franziska SIEGEL, Marcus BAUSER, Detlev SÜLZLE, Simon HOLTON, Michaela BAIRLEIN, Philipp BUCHGRABER, Jözsef BÁLINTT
-
Publication number: 20160263122Abstract: The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: LA represents an optionally substituted methylene or ethylene group; LB represents —N(H)—C(?0)- or —C(?0)—N(H)—; R1 represents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or —N(R7)(Ci-C6-alkyl) group; R2 represents an optionally substituted 5- or 6-membered heteroaryl group; R3 represents an optionally substituted phenyl group.Type: ApplicationFiled: March 17, 2014Publication date: September 15, 2016Inventors: Kai THEDE, William SCOTT, Eckhard BENDER, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PUEHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MOWES, Anja RICHTER, Ludwig ZORN, Ningshu LIU, Ursula MONNING, Franziska SIEGEL
-
Publication number: 20160052898Abstract: The present invention relates to substituted N-biphenyl-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-biphenyl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: March 20, 2014Publication date: February 25, 2016Inventors: Kai THEDE, William Johnston SCOTT, Eckhard BENDER, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PUEHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES, Anja RICHTER, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL
-
Publication number: 20150183773Abstract: The invention relates to novel substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders and tumour disorders.Type: ApplicationFiled: March 10, 2015Publication date: July 2, 2015Inventors: Mario JESKE, Dirk HEIMBACH, Susanne RÖHRIG, Yolanda CANCHO GRANDE, Dirk SCHNEIDER, Ulrich RESTER, Eckhard BENDER, Mark MEININGHAUS, Katja ZIMMERMANN, Dmitry ZUBOV, Anja BUCHMÜLLER, Georges VON DEGENFELD, Christoph GERDES, Michael GERISCH, Mark Jean GNOTH, Kersten Matthias GERICKE
-
Patent number: 8987248Abstract: The invention relates to novel substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders and tumor disorders.Type: GrantFiled: March 12, 2010Date of Patent: March 24, 2015Assignee: Bayer Intellectual Property GmbHInventors: Mario Jeske, Dirk Heimbach, Susanne Röhrig, Yolanda Cancho Grande, Dirk Schneider, Ulrich Rester, Eckhard Bender, Mark Meininghaus, Katja Zimmermann, Dmitry Zubov, Anja Buchmüller, Georges Von Degenfeld, Christoph Gerdes, Michael Gerisch, Mark Jean Gnoth, Kersten Matthias Gericke
-
Publication number: 20140357655Abstract: Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.Type: ApplicationFiled: January 15, 2013Publication date: December 4, 2014Inventors: Olaf Panknin, Stefan Bäurle, Sven Ring, Wolfgang Schwede, Wilhelm Bone, Katrin Nowak-Reppel, Eckhard Bender, Reinhard Nubbemeyer, Mark Jean Gnoth
-
Publication number: 20130252948Abstract: The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular diseases and tumour diseases.Type: ApplicationFiled: May 14, 2013Publication date: September 26, 2013Applicant: BAYER INTELLECTUAL PROPERTY GmbHInventors: Dirk HEIMBACH, Susanne RÖHRIG, Yolanda CANCHO GRANDE, Eckhard BENDER, Katfa ZIMMERMANN, Anja BUCHMÜLLER, Christoph GERDES, Mark Jean GNOTH, Kersten Matthias GERICKE, Mario JESKE
-
Patent number: 8440657Abstract: The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular diseases and tumour diseases.Type: GrantFiled: May 18, 2010Date of Patent: May 14, 2013Assignee: Bayer Intellectual Property GmbHInventors: Dirk Heimbach, Susanne Röhrig, Yolanda Cancho Grande, Eckhard Bender, Katja Zimmermann, Anja Buchmüller, Christoph Gerdes, Mark Jean Gnoth, Kersten Matthias Gericke, Mario Jeske
-
Publication number: 20130005704Abstract: The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.Type: ApplicationFiled: December 26, 2011Publication date: January 3, 2013Applicant: BAYER PHARMA AKTIENGESELLSHAFTInventors: Heinrich Meier, Eckhard Bender, Ulf Brüggemeier, Ingo Flamme, Dagmar Karthaus, Peter Kolkhof, Daniel Meibom, Dirk Schneider, Verena Voehringer, Chantal Fürstner, Jörg Keldenich, Dieter Lang, Elisabeth Pook, Carsten Schmeck
-
Publication number: 20120220563Abstract: The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and tumour disorders.Type: ApplicationFiled: May 19, 2010Publication date: August 30, 2012Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Dirk Heimbach, Susanne Röhrig, Yolanda Cancho Grande, Eckhard Bender, Katja Zimmermann, Anja Buchmüller, Christoph Gerdes, Mark Jean Gnoth, Kersten Matthias Gericke, Mario Jeske
-
Publication number: 20120214788Abstract: The invention relates to novel heteroaryl-substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular diseases and tumour diseases.Type: ApplicationFiled: February 20, 2012Publication date: August 23, 2012Applicant: Bayer Pharma AktiengesellschaftInventors: Dirk Heimbach, Susanne Röhrig, Dirk Schneider, Ulrich Rester, Eckhard Bender, Mark Meininghaus, Katja Zimmermann, Dmitry Zubov, Anja Buchmüller, Georges Von Degenfeld, Christoph Gerdes, Michael Gerisch, Mark Jean Gnoth, Yolanda Cancho Grande, Mario Jeske, Kersten Matthias Gericke
-
Patent number: 8202862Abstract: The invention relates to compounds of the formula to processes for the preparation thereof, and to the use thereof for treatment and/or prophylaxis of cardiovascular diseases and tumour diseases.Type: GrantFiled: May 27, 2010Date of Patent: June 19, 2012Assignee: Bayer Intellectual Property GmbHInventors: Dirk Heimbach, Susanne Röhrig, Yolanda Cancho Grande, Eckhard Bender, Katja Zimmermann, Anja Buchmüller, Christoph Gerdes, Mark Jean Gnoth, Kersten Matthias Gericke, Mario Jeske